Iova yahoo finance according to iova yahoo finance

According to iova yahoo finance, Iovance Biotherapeutics (IOVA) closed yesterday at $9.84, up 2.07% on heavier-than-average volume. Recent analyst forecasts suggest potential upside toward $12.50 in Q3 2024, driven by positive clinical data in the biotech oncology space. Investors tracking the Nasdaq biotech index note sector sentiment improving, which may continue supporting IOVA’s momentum. Iovance Biotherapeutics' share price isn't that far away from its 52-week low. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) develops individualized T-cell therapies to treat solid tumor cancers by harnessing the patient’s immune system. The company’s focus is on Tumor-Infiltrating Lymphocyte (TIL) therapy, a personalized cell therapy in which T-cells are extracted from a patient’s tumor, expanded, and reinfused to fight the cancer. Market sentiment gauges from iova yahoo finance place IOVA in the 78th percentile for analyst buy ratings among small-cap biotech stocks. This reflects increasing institutional confidence as trial results approach key endpoints.